{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:57:22Z","timestamp":1789516642403,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Atypical hemolytic uremic syndrome (aHUS) can result in severe kidney dysfunction, secondary to thrombotic microangiopathy. Eculizumab has been used to treat this disorder, and has resulted in favourable outcomes in both, native and transplanted kidneys. There is limited long term follow up data in kidney transplant recipients (KTRs) who received prevention and treatment with Eculizumab. We report our long term follow up data from our center to address safety and efficacy of this therapy in KTRs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We performed a retrospective analysis of KTRs between January 2009 and December 2018. Clinical diagnosis of aHUS established with presence of thrombotic microangiopathy, acute kidney injury, absence of alternate identifiable etiology. We reviewed clinical data, including genetic testing for complement factor mutations, post-transplant course, and response to therapy including therapeutic and prophylactic use of eculizumab.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Nineteen patients with aHUS received a total of 36 kidney transplants; 10 of them had 2 or more prior kidney transplants. Median age at time of last transplant was 37\u2009years (range 27\u201359), 72% were female (<jats:italic>n<\/jats:italic>\u2009=\u200914), 78% Caucasian (<jats:italic>n<\/jats:italic>\u2009=\u200915), with 61% had live donor transplant (<jats:italic>n<\/jats:italic>\u2009=\u200912) as the last transplant. Eculizumab prophylaxis was given to 10\/19 (56%) at the time of transplantation, with no aHUS recurrence during the follow up. Median duration of follow up was 46 (range 6\u2013237) months. Mean estimated glomerular filtration rate (eGFR) at the time of last follow up was 59.5\u2009ml\/min\/m<jats:sup>2<\/jats:sup>. No infections secondary to encapsulated organisms or other major infectious complications occurred during the follow up.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Eculizumab prophylaxis is safe and effective in KTRs with aHUS. Long term follow up demonstrates that it may be possible to discontinue prophylaxis carefully in selected patients with no evidence of complement mutations.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-020-01847-0","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T06:02:57Z","timestamp":1589954577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome\u2013 a single center experience"],"prefix":"10.1186","volume":"21","author":[{"given":"Sam","family":"Kant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Alasfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1249-2455","authenticated-orcid":false,"given":"Nada","family":"Alachkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"issue":"17","key":"1847_CR1","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676\u201387. https:\/\/doi.org\/10.1056\/NEJMra0902814.","journal-title":"N Engl J Med"},{"issue":"3","key":"1847_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/ajt.12077","volume":"13","author":"ML Quintrec","year":"2013","unstructured":"Quintrec ML, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13(3):663\u201375. https:\/\/doi.org\/10.1111\/ajt.12077.","journal-title":"Am J Transplant"},{"issue":"5","key":"1847_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87(5):1061\u201373. https:\/\/doi.org\/10.1038\/ki.2014.423.","journal-title":"Kidney Int"},{"issue":"3","key":"1847_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701\u201311. https:\/\/doi.org\/10.1016\/j.kint.2015.11.026.","journal-title":"Kidney Int"},{"issue":"1","key":"1847_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"Fadi Fakhouri","year":"2016","unstructured":"Fakhouri, Fadi, MD, PhD, Hourmant, Maryvonne, MD, PhD, Campistol JM, MD, et al: Terminal complement inhibitor Eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68(1):84\u201393. https:\/\/doi.org\/10.1053\/j.ajkd.2015.12.034.","journal-title":"American Journal of Kidney Diseases"},{"issue":"11","key":"1847_CR6","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1111\/j.1600-6143.2009.02817.x","volume":"9","author":"V Chatelet","year":"2009","unstructured":"Chatelet V, Fr\u00e9meaux-Bacchi V, Lobbedez T, Ficheux M, BHd L. Safety and long-term efficacy of Eculizumab in a renal transplant patient with recurrent atypical hemolytic\u2013uremic syndrome. Am J Transplant. 2009;9(11):2644\u20135. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02817.x.","journal-title":"Am J Transplant"},{"issue":"23","key":"1847_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor Eculizumab in atypical hemolytic\u2013uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381. https:\/\/doi.org\/10.1056\/NEJMoa1208981.","journal-title":"N Engl J Med"},{"key":"1847_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fmed.2014.00052","volume":"1","author":"S Alasfar","year":"2014","unstructured":"Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne). 2014;1:52. https:\/\/doi.org\/10.3389\/fmed.2014.00052.","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"1847_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","volume":"98","author":"D Matar","year":"2014","unstructured":"Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation. 2014;98(11):1205\u201312. https:\/\/doi.org\/10.1097\/TP.0000000000000200.","journal-title":"Transplantation"},{"issue":"8","key":"1847_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1432-2277.2012.01497.x","volume":"25","author":"N Alachkar","year":"2012","unstructured":"Alachkar N, Bagnasco SM, Montgomery RA. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int. 2012;25(8):93. https:\/\/doi.org\/10.1111\/j.1432-2277.2012.01497.x.","journal-title":"Transpl Int"},{"issue":"1","key":"1847_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor Eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm. Open Label Trial Am J Kidney Dis. 2016;68(1):84\u201393. https:\/\/doi.org\/10.1053\/j.ajkd.2015.12.034.","journal-title":"Open Label Trial Am J Kidney Dis"},{"issue":"12","key":"1847_CR12","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","volume":"12","author":"J Zuber","year":"2012","unstructured":"Zuber J, Quintrec ML, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337\u201354. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04252.x.","journal-title":"Am J Transplant"},{"issue":"3","key":"1847_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000468528","volume":"136","author":"SM Manani","year":"2017","unstructured":"Manani SM, Virz\u00ec GM, Giuliani A, et al. Hemolytic uremic syndrome and kidney transplantation: a case series and review of the literature. NEF. 2017;136(3):245\u201353. https:\/\/doi.org\/10.1159\/000468528.","journal-title":"NEF"},{"issue":"3","key":"1847_CR14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","volume":"4","author":"AM Siedlecki","year":"2019","unstructured":"Siedlecki AM, Isbel N, Vande Walle J, James Eggleston J, Cohen DJ. Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep. 2019;4(3):434\u201346. https:\/\/doi.org\/10.1016\/j.ekir.2018.11.010.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"1847_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a Nationwide French series comparing children and adults. CJASN. 2013;8(4):554\u201362. https:\/\/doi.org\/10.2215\/CJN.04760512.","journal-title":"CJASN"},{"issue":"3","key":"1847_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000445127","volume":"43","author":"T Zhang","year":"2016","unstructured":"Zhang T, Lu J, Liang S, et al. Comprehensive analysis of complement genes in patients with atypical hemolytic uremic syndrome. AJN. 2016;43(3):160\u20139. https:\/\/doi.org\/10.1159\/000445127.","journal-title":"AJN"},{"issue":"2","key":"1847_CR17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1681\/ASN.V122297","volume":"12","author":"J Caprioli","year":"2001","unstructured":"Caprioli J, Bettinaglio P, Zipfel PF, et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. JASN. 2001;12(2):297\u2013307.","journal-title":"JASN"},{"issue":"4","key":"1847_CR18","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1046\/j.1523-1755.1998.00824.x","volume":"53","author":"P Warwicker","year":"1998","unstructured":"Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998;53(4):836\u201344. https:\/\/doi.org\/10.1046\/j.1523-1755.1998.00824.x.","journal-title":"Kidney Int"},{"issue":"10","key":"1847_CR19","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. CJASN. 2010;5(10):1844\u201359. https:\/\/doi.org\/10.2215\/CJN.02210310.","journal-title":"CJASN"},{"issue":"12","key":"1847_CR20","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1097\/TP.0000000000001909","volume":"101","author":"C Levi","year":"2017","unstructured":"Levi C, Fr\u00e9meaux-Bacchi V, Zuber J, et al. Midterm outcomes of 12 renal transplant recipients treated with Eculizumab to prevent atypical hemolytic syndrome recurrence. Transplantation. 2017;101(12):2924. https:\/\/doi.org\/10.1097\/TP.0000000000001909.","journal-title":"Transplantation"},{"issue":"21","key":"1847_CR21","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V120.21.3472.3472","volume":"120","author":"A Hill","year":"2012","unstructured":"Hill A, Kelly RJ, Kulasekararaj AG, et al. Eculizumab in paroxysmal nocturnal Hemoglobinuria (PNH): a report of all 153 patients treated in the UK. Blood. 2012;120(21):3472. https:\/\/doi.org\/10.1182\/blood.V120.21.3472.3472.","journal-title":"Blood"},{"issue":"12","key":"1847_CR22","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/tri.13022","volume":"30","author":"CM Legendre","year":"2017","unstructured":"Legendre CM, Campistol JM, Feldkamp T, et al. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. Transpl Int. 2017;30(12):1275\u201383. https:\/\/doi.org\/10.1111\/tri.13022.","journal-title":"Transpl Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01847-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-01847-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01847-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T07:18:13Z","timestamp":1621495093000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01847-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1847"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01847-0","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a retrospective chart review study approved by the Johns Hopkins Hospital Institutional Review Board (IRB). Patient\u2019s consent was waived. All ethics in conducting retrospective chart review research were followed closely.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Nada Alachkar is a Section Editor of BMC Nephrology-Transplantation Section.No other financial and non-financial competing interests for any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}